Top

Published in:

01-03-2018 | Original Communication

Continuous subcutaneous apomorphine infusion does not impair the dynamics of cognitive action control in mild to moderate Parkinson’s disease

Authors: Joan Duprez, Jean-François Houvenaghel, Sophie Drapier, Manon Auffret, Dominique Drapier, Gabriel Robert, Marc Vérin, Paul Sauleau

Published in: Journal of Neurology | Issue 3/2018

Abstract

Introduction

Continuous subcutaneous apomorphine infusion (CSAI) is increasingly used in Parkinson’s disease (PD), notably in patients contraindicated for subthalamic deep brain stimulation. Although it has been suggested that CSAI is safe regarding cognition, few studies have actually investigated its effect, especially on cognitive control which is a crucial process for goal-directed behavior. More specifically, its impact on the dynamics of cognitive action control, as reflected by the activation and suppression of impulsive responses, has yet to be investigated, which is the objective of the present study.

Methods

We compared cognitive action control between baseline (M0) and 6 months (M6) after the start of add-on CSAI by administering an oculomotor Simon task to 20 patients with mild to moderate PD. We used the activation–suppression model to determine whether CSAI had an effect on either the impulsive errors made in conflict situations or the suppression of these responses.

Results

We found no difference between M0 and M6 in the congruence effect regarding either reaction time or accuracy, indicating that overall conflict resolution was not influenced by CSAI. Furthermore, the rate of fast errors in the conflict situation and the last slope of the delta plots (reflecting the strength of impulsive response suppression) were unaffected by the treatment. The 95% confidence intervals calculated for the treatment effect on both of these measures fell below the range of usual meaningful effects.

Conclusion

We found no difference between M0 and M6, which strongly suggests that CSAI does not impair the dynamics of cognitive action control.

Rosa-Grilo M, Qamar MA, Evans A, Chaudhuri KR (2016) The efficacy of apomorphine—a non-motor perspective. Parkinsonism Relat Disord 33:S28–S35. https://doi.org/10.1016/j.parkreldis.2016.11.020 CrossRefPubMed

Růzicka E, Roth J, Spacková N et al (1994) Apomorphine induced cognitive changes in Parkinson’s disease. J Neurol Neurosurg Psychiatry 57:998–1001CrossRefPubMedPubMedCentral

Alegret M, Valldeoriola F, Martí M et al (2004) Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson’s disease. Mov Disord 19:1463–1469CrossRefPubMed

De Gaspari D, Siri C, Landi A et al (2006) Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson’s disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. J Neurol Neurosurg Psychiatry 77:450–453CrossRefPubMedPubMedCentral

Drapier S, Gillioz A-S, Leray E et al (2012) Apomorphine infusion in advanced Parkinson’s patients with subthalamic stimulation contraindications. Parkinsonism Relat Disord 18:40–44CrossRefPubMed

Richard Ridderinkhof K, Forstmann BU, Wylie SA et al (2011) Neurocognitive mechanisms of action control: resisting the call of the Sirens. Wiley Interdiscip Rev Cogn Sci 2:174–192CrossRefPubMed

Simon JR (1969) Reactions toward the source of stimulation. J Exp Psychol 81:174CrossRefPubMed

Ridderinkhof KR et al (2002) Activation and suppression in conflict tasks: empirical clarification through distributional analyses. Mechanisms in Perception and Action. Attention and Performance, vol XIX. Oxford University Press Series, Oxford, pp 494–519

van den Wildenberg WPM, Wylie SA, Forstmann BU et al (2010) To head or to heed? Beyond the surface of selective action inhibition: a review. Front Hum Neurosci 4:222. https://doi.org/10.3389/fnhum.2010.00222 PubMedPubMedCentral

10.

Duprez J, Houvenaghel J-F, Argaud S et al (2017) Impulsive oculomotor action selection in Parkinson’s disease. Neuropsychologia 95:250–258. https://doi.org/10.1016/j.neuropsychologia.2016.12.027 CrossRefPubMed

11.

Wylie SA, van den Wildenberg WPM, Ridderinkhof KR et al (2009) The effect of Parkinson’s disease on interference control during action selection. Neuropsychologia 47:145–157CrossRefPubMed

12.

Wylie SA, Ridderinkhof KR, Bashore TR, van den Wildenberg WPM (2010) The effect of Parkinson’s disease on the dynamics of on-line and proactive cognitive control during action selection. J Cogn Neurosci 22:2058–2073. https://doi.org/10.1162/jocn.2009.21326 CrossRefPubMedPubMedCentral

13.

van Wouwe NC, Kanoff KE, Claassen DO et al (2016) Dissociable effects of dopamine on the initial capture and the reactive inhibition of impulsive actions in Parkinson's disease. J Cogn Neurosci 28(5):710–723CrossRefPubMedPubMedCentral

14.

Wylie SA, Claassen DO, Huizenga HM et al (2012) Dopamine agonists and the suppression of impulsive motor actions in Parkinson disease. J Cogn Neurosci 24:1709–1724CrossRefPubMedPubMedCentral

15.

Wylie SA, Ridderinkhof KR, Elias WJ et al (2010) Subthalamic nucleus stimulation influences expression and suppression of impulsive behaviour in Parkinson’s disease. Brain J Neurol 133:3611–3624. https://doi.org/10.1093/brain/awq239 CrossRef

16.

Borgemeester RWK, van Laar T (2017) Continuous subcutaneous apomorphine infusion in Parkinson’s disease patients with cognitive dysfunction : a retrospective long-term follow-up study. Parkinsonism Relat Disord. https://doi.org/10.1016/j.parkreldis.2017.09.025 PubMed

17.

Ribarič S (2012) The pharmacological properties and therapeutic use of apomorphine. Mol Basel Switz 17:5289–5309. https://doi.org/10.3390/molecules17055289

18.

Duprez J, Houvenaghel J-F, Argaud S et al (2016) Enhanced impulsive action selection in middle-aged adults-insights from an oculomotor simon task. Front Aging Neurosci 8:251. https://doi.org/10.3389/fnagi.2016.00251 CrossRefPubMedPubMedCentral

19.

Hoehn MM, Yahr MD (1967) Parkinsonism onset, progression, and mortality. Neurology 17:427. https://doi.org/10.1212/WNL.17.5.427 CrossRefPubMed

20.

Drapier S, Eusebio A, Degos B et al (2016) Quality of life in Parkinson’s disease improved by apomorphine pump: the OPTIPUMP cohort study. J Neurol 263:1111–1119. https://doi.org/10.1007/s00415-016-8106-3 CrossRefPubMed

21.

Martinez-Martin P, Reddy P, Antonini A, Henriksen T, Katzenschlager R, Odin P, Todorova A, Naidu Y, Tluk S, Chandiramani C, Martin A, Chaudhuri KR (2011) Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson’s disease compared to conventional therapy: a real life study of non motor effect. J Parkinsons Dis 1:197–203. https://doi.org/10.3233/JPD-2011-11037 PubMed

22.

Mattis S (1988) Dementia rating scale professional manual. Psychological Assessment Resources, Odessa

23.

Wylie SA, van den Wildenberg W, Ridderinkhof KR et al (2012) Differential susceptibility to motor impulsivity among functional subtypes of Parkinson’s disease. J Neurol Neurosurg Psychiatry 83:1149–1154. https://doi.org/10.1136/jnnp-2012-303056 CrossRefPubMedPubMedCentral

24.

Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri R, Henriksen T, van Laar T, Spivey K, Vel S, Lees A (2017) Double-blind, randomized, placebo-controlled, phase III study (TOLEDO) to evaluate the efficacy of apomorphine subcutaneous infusion in reducing OFF time in Parkinson’s disease patients with motor fluctuations not well controlled on optimized conventional treatment [abstract]. Mov Disord 32(suppl 2)

Title: Continuous subcutaneous apomorphine infusion does not impair the dynamics of cognitive action control in mild to moderate Parkinson’s disease
Authors: Joan Duprez
Jean-François Houvenaghel
Sophie Drapier
Manon Auffret
Dominique Drapier
Gabriel Robert
Marc Vérin
Paul Sauleau
Publication date: 01-03-2018
Publisher: Springer Berlin Heidelberg
Published in: Journal of Neurology / Issue 3/2018
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-017-8721-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Continuous subcutaneous apomorphine infusion does not impair the dynamics of cognitive action control in mild to moderate Parkinson’s disease

Abstract

Introduction

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2018

A common CHRNE mutation in Brazilian patients with congenital myasthenic syndrome

Electrophysiological and behavioral effects of frontal transcranial direct current stimulation on cognitive fatigue in multiple sclerosis

Distinct manifestation of cognitive deficits associate with different resting-state network disruptions in non-demented patients with Parkinson’s disease

A dedicated neurologist at the emergency department during out-of-office hours decreases patients’ length of stay and admission percentages

The MOVES (Motor tic, Obsessions and compulsions, Vocal tic Evaluation Survey): cross-cultural evaluation of the French version and additional psychometric assessment

Risk factors in Swedish young men for amyotrophic lateral sclerosis in adulthood